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590Objective: The Surgical Care Improvement Project (SCIP) has benchmarked 6:00 AM blood glucose levels of
less than 200 mg/dL on postoperative day (POD) 1 and 2 as quality measures of glycemic control in cardiac
surgery. This study was undertaken to (1) determine the incidence of SCIP outliers in patients receiving a con-
tinuous insulin infusion (CII) targeted to maintain perioperative serum glucose levels less than 180 mg/dL after
cardiac surgery, (2) identify the profile of patients who are SCIP outliers, (3) determine whether SCIP outliers
have increased morbidity and mortality, and (4) identify more relevant benchmarks for glycemic control in
patients having cardiac surgery.
Methods: Between January 1, 2008, and April 30, 2011, a total of 832 patients underwent cardiac surgery and
received CII to maintain serum blood glucose levels of less than 180 mg/dL. Patients were divided into 2 groups:
patients compliant with SCIP and SCIP outliers.
Results: The incidence of SCIP outliers was 6.6% (55/832). Patients more likely to be SCIP outliers had
diabetes mellitus (38, 69% vs 250, 32%; P<.0001), a higher hemoglobin A1c (8.74  2.25 vs 7.59  2.90;
P<.0009), and a higher body mass index (31.1  6.5 vs 29.2  5.7; P ¼ .03). However, SCIP outliers had
no increase in morbidity, mortality, or hospital length of stay.
Conclusions: Patients undergoing cardiac surgery may still be SCIP outliers despite CII targeted to maintain
serum glucose levels below 180mg/dL; however, SCIP outliers had no increase in morbidity, mortality, or length
of stay. (J Thorac Cardiovasc Surg 2013;145:590-7)Perioperativeglycemic control bymaintaining serumglucose
at less than 180mg/dL in patients undergoing cardiac surgery
has been found to reduce morbidity, mortality, and hospital
length of stay, decrease the incidence of sternal wound
infections, and enhance long-term survival and freedom
from recurrent ischemic events.1-6 The Society of Thoracic
Surgeons (STS) Practice Guidelines now recommend that
all adults undergoing cardiac surgery, with and without
diabetes mellitus, maintain serum glucose levels below 180
mg/dL for the duration of their postoperative care.7
The Surgical Care Improvement Project (SCIP) is a na-
tional program undertaken to improve outcomes in surgery
and, specifically, to reduce surgical site infections.8 One of
the core SCIP quality measures involves glycemic control
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be less than 200 mg/dL as the indicator of glycemic control
after cardiac surgery. Compliance with these quality
measures is publicly reported on the Centers for Medicare
and Medicaid hospital website and is used to determine
monetary reimbursement for participating hospitals. How-
ever, several studies have questioned the relevance of
SCIP in directly leading to improved surgical outcomes.9-12
Furthermore, the relevance of a single SCIP glucose
measurement in cardiac surgical patients already receiving
a continuous insulin infusion (CII) targeted to achieve
a serum glucose level of less than 180 mg/dL is unknown.
This study was therefore undertaken to (1) determine the
incidence of SCIP outliers in adults undergoing cardiac
surgery and receiving a CII targeted to maintain peri-
operative serum glucose of less than 180 mg/dL, (2)
identify the profile of patients in this cohort who are SCIP
outliers, (3) determine whether SCIP outliers already on
a CII protocol have increased morbidity and mortality, and
(4) identify more relevant benchmarks that can be used to
determine glycemic control in patients undergoing cardiac
surgery.
METHODS
This study was approved by the Boston University Medical Center
Institutional Review Board (Protocol No. H-25760), and informed consent
was obtained from each patient.ery c February 2013
TABLE 1. Patient profiles
Variable
SCIP outlier
(n ¼ 55)
SCIP compliant
(n ¼ 777) P value
Age (y) 64  11 66  12 .25
Sex (M/F) 39/16 546/231 .78
Hypertension (%) 48 (87) 662 (85) .17
Diabetes (%) 38 (69) 250 (32) <.0001
Insulin (%) 22 (58) 76 (30) <.01
Oral (%) 16 (42) 133 (53)
Diet (%) 0 (0) 39 (17
Hyperlipidemia (%) 42 (76) 653 (84) .15
Procedure
CABG 37 (67) 509 (84) .12
CABGþvalve 7 (13) 98 (13)
Valve 11 (20) 170 (22)
Surgical class
Elective 22 (40) 373 (48) .24
Urgent 33 (60) 386 (50)
Emergency 0 (0) 18 (2)
HbA1c 8.74  2.25 7.59  1.90 .0009
Ejection fraction (%) 49.0  14 53  13 .10
BMI (kg/m2) 31.1  6.5 29.2  5.7 .03
All values are mean standard deviation. SCIP, Surgical Care Improvement Project;
M/F, male/female; CABG, coronary artery bypass graft; HbA1c, hemaglobin A1c;
BMI, body mass index.
Abbreviations and Acronyms
3BG ¼ 3-day blood glucose
BMI ¼ body mass index
CABG ¼ coronary artery bypass surgery
CII ¼ continuous insulin infusion
HbA1c ¼ hemoglobin A1c
ICU ¼ intensive care unit
MHG ¼ mean hospital glucose
POD ¼ postoperative day
SCIP ¼ Surgical Care Improvement Project
STS ¼ The Society of Thoracic Surgeons
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MEligibility and Exclusion Criteria
This was an observational, single-center study involving adult patients
(both with and without diabetes) undergoing cardiac surgery from January
1, 2008, to August 30, 2011. Patients undergoing coronary artery bypass
surgery (CABG), valve repair and replacement, and combinations of
CABG plus valve surgery were included. Patients undergoing aneurysm
repair with or without deep hypothermic circulatory arrest were excluded.
Glycemic Control Protocols
All patients received a CII (100 units of regular insulin in 100 mL of
0.9% normal saline) to maintain serum glucose between 120 and 180
mg/dL. Infusions were initiated on anesthetic induction and continued dur-
ing the periods of cardiopulmonary bypass and cardioplegic arrest, after the
discontinuation of cardiopulmonary bypass, and for at least 18 hours in the
intensive care unit (ICU) as previously described.13 After the 18-hour ICU
period, patients were transitioned off the CII using either short- or long-
acting insulin agents to maintain a fasting glucose level between 90 and
120 mg/dL and postsupper glucose level of less than 180 mg/dL. Patients
were transitioned off CII when they (1) maintained a stable intravenous in-
sulin infusion rate for at least for 4 hours, (2) were extubated and off ino-
tropic agents, and (3) were ready to begin oral, enteral, or parenteral
nutrition. Serum glucose was measured every 30 minutes in the operating
room and hourly in the ICU during CII. Blood glucose measurements were
obtained using arterial catheters and finger sticks and were measured with
the use of point-of-care glucose meters. The mean hospital glucose (MHG)
measurement represents the average of all glucose values obtained during
the hospital stay. Three-day blood glucose (3BG) values consisted of the
average of all glucose values obtained from the end of anesthesia through
the second POD (72 hours). SCIP glucose values represent the mean 6:00
AM glucose value for patients on POD 1 and POD 2.
Operative Techniques
Standard operative and anesthetic techniques were used in all patients.
Myocardial protection was achieved with multidose infusions of antegrade
and retrograde cold (4C) blood (hematocrit ¼ 20%) potassium (28 mEq/
L) cardioplegia supplemented with mild systemic (35C) and topical (cold
saline lavage at 4C) hypothermia. All vessels with at least a 50% stenosis
were bypassed and each patient received at least 1 internal thoracic artery
graft.
Outcomes Measured
In addition to parameters of glycemic control, major adverse events
were also documented. These included 30-day mortality, the incidence of
myocardial infarctions assessed by both enzyme and electrocardiographic
changes as previously described,2 the incidence of cerebrovascular acci-
dents, defined as a persistent neurologic deficit lasting 24 hours or more,
the incidence of deep sternal wound infections, defined as any infectionThe Journal of Thoracic and Careaching or directly involving the sternum, and the incidence of atrial fibril-
lation that lasted longer than 15 minutes. All patients received postopera-
tive beta-blockers and were continuously monitored on telemetry during
their entire postoperative stay. In addition, secondary outcomes that were
assessed included time on the ventilator (defined as time of admission to
the ICU to the time of extubation), length of ICU stay, and length of
hospital stay, all of which were standardized using fast-track protocols.
Patients were also assessed for a clinical reason for SCIP ‘‘failure’’ by
an endocrinologist intimately involved in glycemic control protocols.
Statistical Analyses
Data were summarized using the mean standard deviation for contin-
uous variables and the number and percentage for categorical variables us-
ing statistical analysis systems (SAS, version 9.0; SAS Institute, Inc, Cary,
NC). SCIP compliance was determined prospectively by a hospital com-
mittee assigned to track 6:00 AM glucose on POD 1 and POD 2. All glucose
levels were adjudicated prospectively in real time for accuracy and vali-
dated using retrospectively collected data. Comparison between SCIP com-
pliant subjects and SCIP outliers was performed in bivariate analyses using
2-sample t tests for continuous variables and c2 or Fisher’s exact tests for
categorical data. Association of SCIP compliance was assessed with cate-
gorical surgical outcomes and continuous glucose outcomes (ie, 3BG) via
odds ratios and 95% confident intervals using logistic regression analyses.RESULTS
The results are summarized in Tables 1 to 3 and Figures 1
to 3. The study population comprised 832 patients, 546
having isolated CABG, 105 having CABG plus valve
surgery, and 181 having isolated valve procedures. In this
patient cohort, there were 55 (6.6%) SCIP outliers (Table
1). Factors that did not predict SCIP failures included
age, sex, ejection fraction, surgical class (elective, urgent,rdiovascular Surgery c Volume 145, Number 2 591
TABLE 2. Reasons for SCIP failure
Variable n (%)
Inadequate transition from CII to SQ insulin 14 (26.5)
Delay in initiating insulin infusion 14 (26.5)
No cause 13 (25)
CII protocol violation 7 (12)
Lapse in glucose monitoring 4 (8)
Insulin infusion stopped without transition to SQ insulin 3 (2)
All values are mean  standard deviation. SCIP, Surgical Care Improvement Project;
SQ, subcutaneous; CII, continuous insulin infusion.
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FIGURE 1. A, Surgical Care Improvement Project (SCIP) compliant.
Hospital glucose values for an SCIP compliant patient. The arrows denote
glucose values for 6:00 AM on the first and second postoperative days. Note
that despite being SCIP compliant, a significant number of values were
above The Society of Thoracic Surgeons and SCIP guidelines throughout
the hospital stay. B, SCIP outlier. Hospital glucose values for a type 2 di-
abetic patient who was an SCIP outlier. The arrows denote glucose values
for 6:00 AM on the first and second postoperative days. Note that despite be-
ing an SCIP outlier, the majority of glucose values were within The Society
of Thoracic Surgeons and SCIP guidelines.
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Memergency), the presence of hypertension or hyperlipid-
emia, or the type of procedure performed. Three factors
characterized patients who were SCIP outliers. They were
more likely to have diabetes mellitus (38 [69%] vs 250
[32%]; P<.0001) and be receiving insulin treatment (22
[58%] vs 76 [30%]; P<.01). SCIP outliers showed higher
preoperative hemoglobin A1c (HbA1c) levels indicative of
poor glycemic control in the months preceding surgery
(8.74  2.25 vs 7.59  1.90; P<.0009). In addition, they
had significantly higher body mass indexes (BMIs;
31.1  6.5 kg/m2 vs 29.2  5.7 kg/m2; P ¼ .03). A logistic
regression was used to determine the relationship between
BMI and HbA1c. When applied to all subjects and control-
ling for serum creatinine level, BMI and HbA1c were both
independently associated with being an SCIP outlier. How-
ever, when we isolated patients with previously diagnosed
diabetes mellitus (n ¼ 288), while HbA1c remained signif-
icant, BMI was no longer a significant risk factor for failing
the SCIP measure in this subgroup. Table 2 lists the reasons
for SCIP failure. The most common causes were inadequate
transition from CII to subcutaneous insulin (14; 26.5%) and
a delay in initiation of the insulin infusion (14; 26.5%). In
13 (25%) patients, no clear cause could be determined.
Other factors included an infusion protocol violation
(7; 12%), a lapse in glucose monitoring (4; 8%), and failure
to transition to a subcutaneous insulin dose once the CII was
terminated (3; 2%).
Table 3 shows the outcomes of SCIP outliers. SCIP out-
liers had no significant difference in 30-day mortality, myo-
cardial infarction, permanent strokes, deep sternal woundTABLE 3. Postoperative outcomes
Variable
SCIP outlier
(n ¼ 55)
SCIP compliant
(n ¼ 777)
P
value
Thirty-day mortality (%) 1 (1.8) 13 (1.7) .55
Myocardial infarction (%) 1 (1.8) 11 (1.4) .52
Permanent stroke (%) 1 (1.8) 7 (0.9) .39
Deep sternal infection (%) 0 (0) 3 (0.4) 1.00
Ventilatory support>24 h (%) 5 (9.0) 52 (6.7) .38
Multisystem failure (%) 1 (1.8) 7 (0.9) .43
Atrial fibrillation (%) 9 (16.3) 235 (30.3) .05
Hospital length of stay 11.69  11.02 9.75  7.83 .20
All values are mean  standard deviation. SCIP, Surgical Care Improvement Project.
592 The Journal of Thoracic and Cardiovascular Surginfections, ventilatory support for more than 24 hours, mul-
tisystem failure, or hospital length of stay. The incidence of
atrial fibrillation appeared to be less in patients who were
SCIP outliers (9, 16.3%, vs 235, 30.3%; P ¼ .05), even af-
ter controlling for HbA1c and serum creatinine.
Figure 1, A and B, shows the limitations of SCIP in deter-
mining glycemic control. Figure 1, A, shows the serum
glucose values in a patient who is SCIP compliant on
PODs 1 and 2. However, as shown in the figure, a significant
percentage of these values exceeded both STS and SCIP
guidelines throughout the postoperative period. Figure 1,
B, shows glucose values for a patient with type 2 diabetes
not compliant with SCIP on POD 2. Nevertheless, this pa-
tient maintained both the STS and SCIP guidelines for theery c February 2013
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FIGURE 2. Surgical Care Improvement Project versus hospital mean glu-
cose. Day 1 outliers were compliant on day 2. Day 2 outliers were compli-
ant on day 1. All groups have hospital mean glucose values that are within
The Society of Thoracic Surgeons and Surgical Care Improvement Project
guidelines. POD, Postoperative day.
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FIGURE 3. Three-day blood glucose. Surgical Care Improvement Project
(SCIP) outliers have higher 3-day blood glucose values than SCIP compli-
ant patients but are well within The Society of Thoracic Surgeons and SCIP
guidelines.
McDonnell et al Perioperative Managementremainder of the hospital stay. The limitations of SCIP as
a measure of glycemic control are further highlighted in
Figure 2. Glucose levels at 6:00 AM in SCIP outliers on
POD 1 decreased to compliant levels on POD 2
(210  5.6 mg/dL vs 137  28 mg/dL; P<.001). Patients
who were SCIP outliers on day 2 had compliant glucose
levels on day 1 (230  39 mg/dL vs 142  23 mg/dL;
P< .001). MHG showed that although SCIP outliers on
day 1 had significantly higher glucose levels than SCIP out-
liers from day 2 and SCIP compliant patients, MHG was
consistent with STS and SCIP guidelines (154  61
mg/dL SCIP outliers day 1; P<.001; vs 147  56 mg/dL
SCIP outliers day 2, and 144 48 mg/dL SCIP compliant).
When early postoperative glycemic control using the 3BG
index was assessed (Figure 3), SCIP outliers were also con-
sistent with STS and SCIP guidelines, although patients
noncompliant with SCIP continued to show higher glucose
values (162  19 mg/dL vs 141  6 mg/dL; P<.001).
Overall, 430 or approximately half of the entire cohort
had at least 1 glucose value less than 70 mg/dL during the
course of their entire hospital stay. There was no differ-
ence in the incidence of hypoglycemia between SCIP out-
lier and SCIP compliant patients. Among the patients who
did experience hypoglycemia, this represented only 1.2%
of all their hospital glucose values. There was no associ-
ated morbidity in any of the patients in whom hypoglyce-
mia developed.P
MDISCUSSION
Our study has shown that in patients undergoing cardiac
surgery and receiving CII to maintain a serum glucose level
of less than 180 mg/dL, a certain percentage of patients will
be SCIP outliers. Outliers are more likely to have diabetesThe Journal of Thoracic and Canecessitating insulin, have higher HbA1c levels, and in-
creased BMI. Despite being SCIP outliers, these patients
had no increase in postoperative morbidity, mortality, or
length of hospital stay. Similar results were found by Mur-
phy and coworkers,9 who studied the incidence of SCIP
compliance in 108 patients undergoing cardiac surgical pro-
cedures. Although each patient received CII designed to
maintain serum glucose levels between 100 and 140
mg/dL, 10 (9%) patients were found to be SCIP outliers.
Glycemic control was assessed by the average blood glucose
in the initial 48 hours postoperatively, the duration of hyper-
glycemia (percentage of time with blood glucose> 200
mg/dL), and the intensity of the implementation of the insu-
lin infusion (defined as the number of blood glucose checks
per hour on the insulin infusion). The average mean blood
glucose between the SCIP compliant patients and outliers
was 148 2 versus 203 10 mg/dL (P<.0001). However,
the postoperative percentage of time that was spent with
a blood glucose level of more than 200 mg/dL was higher in
SCIP compliant patients (14%  0.2% vs 0.48%  4%;
P<.0001). The number of glucose checks per hour tended
to be higher in the noncompliant group, indicating that
SCIP noncompliance was not due to less intense implemen-
tation of the insulin infusion protocol. Murphy and co-
workers9 concluded that even the use of CII targeted to
a blood glucose of less than 140 mg/dL did not guarantee
compliance with SCIP even though more frequent adjust-
ments weremade in the SCIP outlier group. Stulberg and co-
workers10 sought to examine the relationship between SCIP
adherence andpostoperative infection rates ina retrospective
study using the Premier Prospective database. This involved
398 hospitals and 405,720 patients. The incidence of surgi-
cal infections was 1.1% in SCIP compliant patients versus
1.5% in noncompliant patients. The authors were not able
to demonstrate a relationship between SCIP adherence and
a decreased incidence of infections. This is in agreementrdiovascular Surgery c Volume 145, Number 2 593
Perioperative Management McDonnell et al
P
Mwith other studies that have failed to validate the effective-
ness of SCIP in reducing infection rates.11,12
It is not surprising that the 2 isolated SCIP glucose mea-
surements do not predict postoperative outcomes. Studies
have shown that metrics that incorporate glucose values
over longer time periods are prognostically superior to
data from just the first 24 or 48 hours of a patient’s hospital-
ization. Furnary, Wu, and Bookin14 assessed the efficacy of
glycemic control using 3BG in 1980 patients undergoing
cardiac surgery using CII. This was calculated from an av-
erage of all glucose values on the day of surgery and the first
and second PODs. An increase in 3BG was an independent
predictor of postoperative mortality (P<.001). Changes in
3BG were also predictive of deep sternal wound infections,
longer hospital lengths of stay, the need for blood transfu-
sions, new-onset atrial fibrillation, and low cardiac output
syndrome. Kosiborod and coworkers15 also sought to deter-
mine which metrics of glycemic control would best predict
hospital mortality in patients admitted with an acute myo-
cardial infarction. In this study, 3 parameters of glycemic
control were compared with a single admission glucose
value in the ability to predict hospital mortality. MHG
was the average of each patient’s glucose value during the
hospitalization. A time-averaged glucose value was the
area under the curve of all glucose values during a specified
time period divided by the length of the time period. The hy-
perglycemic index was the area under the curve of hyper-
glycemic glucose values over a particular time period.16
Each of these methods was evaluated over the first 24 hours,
48 hours, and for the entire hospitalization, and they were
better predictors of hospital mortality than a single admis-
sion glucose level. MHG over the entire hospital stay was
found to be the easiest and most practical parameter to
assess glycemic control and its relationship to hospital sur-
vival. The authors concluded that metrics that incorporated
glucose values over longer time periods were prognostically
superior to a single glucose value or data obtained from just
the first 24 or 48 hours of a patient’s hospitalization after an
acute myocardial infarction.
Achieving glycemic control in the perioperative period re-
quires a multidisciplinary approach that includes representa-
tives from nursing, anesthesiology, pharmacy, surgery, and
endocrinology. At our own institution, we formed a Perioper-
ative Glycemic Control Committee to help meet SCIP guide-
lines. A representative from this committee receives SCIP
outcome data on a monthly basis and reviews each case that
does not meet the glycemic target. Committee members
then provide direct feedback to the individual disciplines to
make necessary adjustments or identify areas of deficiencies.
Our study is limited in that it was retrospective and we
were not able to assess in real time the causes for SCIP fail-
ure. Although we did review in detail the hospital records
for all patients with SCIP failure, we may not have been
able to account for any undocumented changes in clinical594 The Journal of Thoracic and Cardiovascular Surgconditions that may have also been responsible for SCIP
outliers.
Our own data corroborate the findings of these studies
that have shown that isolated serum blood glucose values
do not accurately predict patient outcomes and do not ade-
quately represent glycemic control during the hospital stay.
Therefore, failure to meet SCIP glucose guidelines should
not imply substandard care for these patients having cardiac
operations. Adherence to SCIP glycemic values is only 1 as-
pect of effective patient care. Morbidity and mortality in pa-
tients undergoing cardiac surgery are likely to be influenced
by other factors independent of glycemic control. Hence,
SCIP benchmarks for glycemic control should not be the
only metric for reporting operative outcomes and determi-
nation of hospital monetary reimbursements.
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Dr Anthony P. Furnary (Portland, Ore). Dr McDonnell, thank
you for a beautiful and very concise presentation. We can all be
frustrated by this SCIP measure. I think all in this room can agree
that the SCIP benchmarks that have been put forth are really scien-
tifically unfounded, and, as you have said, inaccurate. To me, they
make little sense. As you have shown, being an outlier at 6:00 AM
on the first or second day really has nothing at all to do with the
glycemic state of the patient in the first 3 days.
Just as the SCIP glycemic benchmarks have nothing to do with
glycemic state, I think it is important to note that tight glycemic
control has nothing to dowith cardiac surgery outcomes in patients
who do not have diabetes. This is a really important point. I want to
repeat it. There has not been a single study showing that tight gly-
cemic control alters cardiac surgery outcomes in patients who do
not have diabetes. The only outcomes benefits that have ever
been shown are in patients who have diabetes or in surgery patients
who are receiving total parenteral nutrition for more than 5 days.
A lot of authors have missed that important caveat. It is impor-
tant because it comes as no surprise, then, that any study that com-
bines both patients with diabetes and those without diabetes in its
study population and looks at glycemia-related outcome end
points will find that those glycemia-related outcomes are preor-
dained to be what everybody now calls ‘‘noninferior.’’ Thus it
does not matter whether you look at target blood glucose level,
moderate versus tight glucose control, or a glycemic SCIPmeasure
or you look at actual achieved 3BG; you will always end up with
a noninferior outcome.
Furthermore, in patients with diabetes, the achieved blood glu-
cose levels are always either at the upper end of the target blood
glucose range or, more frequently above that target range. If you
wanted to get 100% compliance within a target, say you wanted
to be 100% less than 180 mg/dL, then you would have to target
150 mg/dL to get everybody there, to less than 180 mg/dL. I
have 3 questions.
First, did you get a chance to analyze the outcomes of just your
diabetes subset of patients with regard to 3BG and SCIP
compliance?
Dr McDonnell. Thank you very much, Dr Furnary, for that ex-
cellent summary. I agree with the majority of your points. You are
absolutely right that the majority of the available prospective data
in group of patients who are newly revascularized supports the
concept that glycemic control reduces the excess risk seen in pa-
tients with diabetes having CABG surgery. Not all data are consis-
tent with this benefit being unique to patients with diabetes,
however, and subgroup analyses of larger studies suggest CABG
patients without diabetes may benefit substantially from postoper-
ative intensive insulin therapy.
I did look at the diabetes CABG subset. This represented 28% of
the entire cohort, so it was a small subset. Just of note, 75% of the
operations in this data set were CABG and 37% of the total group
had a prior diagnosis of diabetes.
We found that 3BG was almost the same between the patients
with diabetes and those without diabetes, 148 mg/dL versus 135
mg/dL, respectively, reflecting that all patients receive the same
glycemic care perioperatively. We did not see a difference in out-
comes between these groups, presumably for 2 reasons: (1) the
glucose difference was minimal; (2) the event rate was low, asThe Journal of Thoracic and Cawould be expected in a group of this size in many centers. Our pre-
vious speaker noted that the mortality reduction seen over the past
10 or 15 years in cardiac surgery is profound depending on the data
set you look at, and it is now difficult to show a difference in out-
comes owing to any single intervention, certainly in mortality.
Dr Furnary.As you know, we have developed the 3BG because
it covers every component of glycemia-related risk throughout the
postoperative period. SCIP decided not to use 3BG or not to use
any composite outcome for several reasons: (1) a composite out-
come is difficult to collect; (2) it is complex to collect; and (3) it
is costly to collect. What would your recommendation be to
SCIP? Furthermore, what is your recommendation for the STS
in regard to glycemic metrics for patients having cardiac surgery?
It is my opinion that the STS really ought to be in charge of this and
define a glycemia-related metric for all patients requiring cardiac
surgery—and use one that makes scientific sense. What should we
collect in the STS database and what should we tell SCIP that they
ought to collect for some sensible scientifically related composite
glucose measurement?
Dr McDonnell. Thank you for your question. First of all, I am
pleased to be part of this conversation, because I think that it is not
an easy answer and we need to discuss it across all involved disci-
plines. I would be happy, as would many of my colleagues, with
a measurement that involved more than 1 or 2 measurements to ar-
rive at a true mean and specifically avoid isolated measurements,
which are not valid as tools to assess overall glycemic control.
As an endocrinologist, I find it concerning that we are using iso-
lated measurements to judge the glycemic care of our patients hav-
ing cardiothoracic surgery. SCIP could potentially calculate 3BG
on a subset of patients randomly selected and report that in the
form of an audit, or we could collect 4 to 8 measurements over
the course of 2 to 3 days. The SCIP monitors may have difficulty
with these more complex measures inasmuch as it would increase
time required to collect data, and that would come at a cost. How-
ever, the conversation needs to continue, and, I agree, STS needs to
be in the forefront.
Dr Furnary. Last question:We know that 75% of the SCIP ‘‘vi-
olations’’ (I call them violations) were caused by a delayed start,
poor transition from intravenous to subcutaneous, or some other
protocol violation, and the remaining ones were caused just be-
cause they were on the protocol and were in that group of patients
who end up higher than the protocol target. We also know that the
actual achieved glucose is often higher than the target. Shouldn’t
we therefore just all lower our upper target range and to say 150
mg/dL and keep all our patients on insulin drip protocols for 3
days instead of just 18 hours? That way, all of the glycemia-related
risks are fully covered. This is what we have done in Portland, and
we end up having 100% SCIP compliance on this glycemic mea-
sure, so it is not so frustrating anymore. We just forget about the
SCIP thing, because it always works.
Dr McDonnell. I will be frank that it took us time, but we have
found that many of the elements related to SCIP failure that I noted
are remediable. We have remediated many of them in the past 1 to
2 years so that we are at 100% compliance for most months over
the past year. We have been over 95% for 2 years. The goal can
be reached in most patients inasmuch as insulin is certainly effec-
tive. However, reaching the SCIP goal, as we have shown, does not
have significant meaning for the patients. Of importance here isrdiovascular Surgery c Volume 145, Number 2 595
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not merely an attempt to arrive temporarily at the 6:00 AM target of
less than 200 mg/dL, after which control may be abandoned.
What I would also say is that intravenous insulin therapy that is
prolonged after cardiothoracic surgery with subcutaneous insulin
to cover meals is very elegant and is a beautiful therapy. However,
I just do not think it is available to every institution. For many rea-
sons, we decided to master the subcutaneous transition by day 2,
and that involved a team of providers, including me and another
attending, with fellows, pharmacists sometimes, and also midlevel
providers, who can be specifically trained to manage intensive sub-
cutaneous insulin in patients having cardiothoracic surgery.
I would say either way it is accomplishable, and whether you
are doing a prolonged insulin infusion on the step-down unit or
early transition to scheduled subcutaneous insulin, an enormous
amount of commitment to both the nurses and to patients is
required, and you know that better than anyone else.
Dr Lars G. Svensson (Cleveland, Ohio). Dr McDonnell, con-
gratulations on a very important and timely study. Unfortunately,
this is something that we are going to have to deal with increas-
ingly, as you, I am sure, are all too aware. At the moment, there
are some 70 patient and outpatient measures that are imposed on
institutions, and at the last count I saw, they are going up to about
120. Increasingly, we are going to be playing defense against all
these various quality measures, and it certainly is a challenge for
those that have to deal with responding to this and observing the
quality of our departments.
As you know, the bump-up in sugar after surgery is a normal re-
sponse to trauma.We all learned that in physiology, and our trauma
surgery colleagues have had to deal with the same issue. Unfortu-
nately, getting the SCIP measures changed has been very difficult.
As you know, the time interval, which is now measured, will be
changing. Fortunately, for those of you who had to deal with the
issue of cold patients in the ICU, we managed to convince various
people that the SCIP measure for that was completely wrong, that
we would be doing patients harm if we rewarm them after surgery
to the point that they are normothermic with the pump. So they did
respond to that.
In response to the issue of blood sugars, we went through vari-
ous changes to try to deal with this issue. We noticed that blood
sugar levels rose in patients who received vancomycin with a glu-
cose carrier; patients who were sicker, who usually went up to the
ICU late in the day or were on epinephrine and also had an increase
in their blood sugar levels. So we recommended various things,
and our nurses were very helpful. For example, a 10 o’clock
glucose value that rises above 160 mg/dL we recheck at 3 o’clock
to try to meet this very measure. The danger in this measure
aggressively is particularly that the patients could become
hypoglycemic.
I have a couple of questions. The categories of complications
that you looked at were fairly broad. The ones as a surgeon I would
worry about as potentially being a factor with high sugars and di-
abetes is in the patients with bilateral internal thoracic arteries and
the risk of wound infection. We know they have a higher risk. Do
you have the numbers to look at that subcategory of patients? Your
incidence of multiple organ failure was remarkably good and low,
but that may be another place where high sugars may play a role as
also with lactic acidosis. Did you look at these subgroups?596 The Journal of Thoracic and Cardiovascular SurgMy final question concerns talk about a National Institutes of
Health study within the cardiothoracic cooperative network look-
ing at this very issue. Is this something that you think should be
taken further?
Dr McDonnell. Thank you very much. I echo your sentiment
and your comments about the strategies that you have used to im-
prove or to reach the SCIP measure and your concern for the po-
tential to go overboard with targeted insulin therapy to attain
a glucose goal, placing patients at risk.
To answer your first question, we do not have the graft type in
this data set, specifically the bilateral internal thoracic arteries,
but we have discussed this as a variable that may be significant.
Your second question concerned the fact that SCIP is linked to
monetary reimbursement and to judging providers and their care.
I think it should go to wherever committee or organization it could
go to in order to make rationale change. Larger multi-institutional
studies are costly, but if they can be used to assess the relevance of
several SCIP measures, it may be of value. In my experience and
opinion, once a program has made the effort to control glucose
and if this can be proven or established by the institution, it is frus-
trating to have to address the randommiss, the randomSCIP outlier
who is not at increased risk of poor outcomes. Unfortunately, at our
institution we continue to have to respond to SCIP reviewers by
spending up to an hour per case trying to determine and document
why a patient had a glucose elevation for a few hours of their entire
stay, which likely has no relevance to their care. Additionally, we
are asked how to prevent this from happening, which, as we have
shown, is impossible to say for all patients inasmuch as in at least
25% of cases there is no identifiable reason for the hyperglycemic
event. This is consistent with the idea that transient physiologic hy-
perglycemia can be unpredictable after cardiothoracic surgery sur-
gery, which, despite having little to no clinical consequence,
currently has significant administrative consequence.
Dr Thomas M. Beaver (Gainesville, Fla). I would caution
against totally throwing SCIP out. I believe there is a ‘‘culture ef-
fect’’ in trying to make things better. I would also remind the audi-
ence that glucose is just one of the many SCIP measures, including
getting the antibiotics in on time during the time out with the anes-
thesiologist; stopping the antibiotics; appropriate choice of antibi-
otics; and warming patients. You can also look at the SCIP overall
composite score.Whatwe found at our own institution is that, aswe
have improved our SCIP composite score, our rate of global class I
surgical infections have decreased by 50% across the board.
Have you had a chance to look at your SCIP composite score in
this group of patients to determine whether that may have had any
effect?
Dr McDonnell. Thank you for your comment. I think that is
such an important way to end this session. SCIP is important in
the way it improved glycemic control and other evidence-based
practice in many institutions. Institutions should be held account-
able for their practice of evidence-based care, and this is
unquestionable for the sustained achievement of optimal patient
outcomes. The priority with SCIP continues to be in line with cli-
nicians, which is to optimize clinical outcomes.Whatwe and others
have tried to highlight, however, is that the parameters selected
have to be simple to measure as well as evidence-based and at min-
imum reflective of the actual practice. Otherwise, the SCIP culture
becomes a negative force as an unintended consequence.ery c February 2013
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knows the answer to this. I do not know whether the composite
score for cardiothoracic surgery has been linked to outcomes in
our institution. I do know that we have extremely low infection
rates, as many hospitals do now, after the institution of manyThe Journal of Thoracic and CaSCIP measures, not just glucose control. But I do not know
whether Dr Lazar wants to comment on that.
Dr Lazar. In brief, the answer is no, we have never ever been
able to correlate any of the SCIP measures with infection in our
institution.rdiovascular Surgery c Volume 145, Number 2 597
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